Should vasopressin be tapered after noradrenaline (norepinephrine) is completely stopped in a patient with shock or severe hypotension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vasopressin Weaning Strategy in Shock

Vasopressin should be discontinued LAST, after norepinephrine has been completely stopped, to avoid hemodynamic instability and rebound hypotension.

Evidence-Based Weaning Protocol

FDA-Approved Tapering Sequence

The FDA label provides explicit guidance on vasopressin withdrawal: after target blood pressure has been maintained for 8 hours without the use of catecholamines, taper vasopressin by 0.005 units/minute every hour as tolerated to maintain target blood pressure 1. This clearly indicates vasopressin should only be weaned after catecholamines (including norepinephrine) are discontinued.

Clinical Evidence Supporting This Approach

  • Discontinuing vasopressin before norepinephrine results in a 74% incidence of hemodynamic instability compared to only 16.7% when vasopressin is stopped last (P < 0.01) 2

  • When vasopressin is withdrawn first, hemodynamic instability occurs significantly faster (median 5 hours vs 15 hours, P < 0.01) 2

  • Rebound hypotension is a well-documented complication of premature vasopressin cessation, often requiring the drug to be administered for several days to avoid this phenomenon 3

Physiologic Rationale

  • Vasopressin deficiency is a known consequence of septic shock, with endogenous levels decreasing to normal range within 24-48 hours despite ongoing shock 4

  • Vasopressin acts through V1 receptors on vascular smooth muscle, providing a complementary mechanism to α1-adrenergic stimulation by norepinephrine 5

  • The non-adrenergic mechanism of vasopressin makes it particularly valuable as catecholamine requirements decrease, preventing the hemodynamic collapse that occurs when both pathways are simultaneously withdrawn 2

Practical Weaning Algorithm

  1. Maintain both agents until hemodynamic stability is achieved for at least 8 hours 1

  2. Wean norepinephrine first by decreasing the dose gradually (typically by 0.05 μg/kg/min decrements) while maintaining vasopressin at a fixed dose of 0.01-0.03 units/minute 6, 5

  3. Discontinue norepinephrine completely once the dose reaches approximately 0.2 μg/kg/min and blood pressure remains stable 5

  4. Begin vasopressin taper only after norepinephrine is stopped and 8 hours of stability without catecholamines has been achieved 1

  5. Taper vasopressin slowly by 0.005 units/minute every hour, monitoring for hypotension 1

Critical Pitfalls to Avoid

  • Never discontinue vasopressin first - this is associated with a 4-fold increase in hemodynamic instability requiring fluid boluses, increased norepinephrine requirements, or addition of alternative vasopressors 2

  • Do not use vasopressin as monotherapy - it must never be the sole vasopressor agent and should always be used in conjunction with norepinephrine 5, 6

  • Avoid doses above 0.04 units/minute except as salvage therapy, as higher doses are associated with cardiac, digital, and splanchnic ischemia 4

  • Monitor closely during the first 5-15 hours after vasopressin discontinuation as this is when hemodynamic instability most commonly occurs 2

References

Research

Terlipressin for norepinephrine-resistant septic shock.

Lancet (London, England), 2002

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Vasopressin during cardiopulmonary resuscitation and different shock states: a review of the literature.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006

Guideline

Vasopressin Dosage and Titration in Sepsis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.